Literature DB >> 10986153

AT(1) and AT(2) receptors in the kidney: role in disease and treatment.

H M Siragy1.   

Abstract

All components of the renin-angiotensin system (RAS) are present in the kidneys and constitute a functioning renal RAS. Angiotensin II (Ang II) receptor subtypes AT(1) and AT(2) have been identified in the afferent and efferent arterioles, glomeruli, mesangial cells, and proximal tubules. AT(1) receptors regulate vasoconstriction and sodium and water reabsorption, as well as promote cell growth, proliferation, and collagen matrix deposition. Recent animal studies are elucidating the role of the less well understood AT(2) receptors. The AT(2) receptors appear to counterbalance the AT(1) receptors by increasing the production of bradykinin, nitric oxide, and cyclic guanosine monophosphate-mediating vasodilation and by promoting cell differentiation, antiproliferation, and apoptosis. Ang II subtype 1 receptor blockers prevent Ang II activation of the AT(1) receptor while leaving the AT(2) receptor open to Ang II stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986153     DOI: 10.1053/ajkd.2000.9684

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

Review 1.  Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

Authors:  M J Dumoulin; D Lamontagne; G Molinaro; A Adam
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model.

Authors:  Julia L Cook; Richard N Re
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

3.  Inhibition of ACE activity contributes to the intestinal structural compensation in a massive intestinal resection rat model.

Authors:  Wensheng Wang; Weidong Xiao; Lihua Sun; Chaojun Zhang; Guoqing Chen; Hua Yang
Journal:  Pediatr Surg Int       Date:  2012-03-24       Impact factor: 1.827

4.  AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney.

Authors:  Hyung Eun Yim; Mee Kyung Kim; In Sun Bae; Ji Hae Kim; Byung Min Choi; Kee Hwan Yoo; Young Sook Hong; Joo Won Lee
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

5.  The association of plasma prorenin level with an oxidative stress marker, 8-OHdG, in nondiabetic hemodialysis patients.

Authors:  Yoshiyuki Morishita; Shiho Hanawa; Takuya Miki; Taro Sugase; Yasuhiro Sugaya; Junko Chinda; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-01-15       Impact factor: 2.801

6.  Intestinal intraepithelial lymphocyte derived angiotensin converting enzyme modulates epithelial cell apoptosis.

Authors:  B E Wildhaber; H Yang; E Q Haxhija; A U Spencer; D H Teitelbaum
Journal:  Apoptosis       Date:  2005-12       Impact factor: 4.677

7.  Modulation of mouse intestinal epithelial cell turnover in the absence of angiotensin converting enzyme.

Authors:  Emir Q Haxhija; Hua Yang; Ariel U Spencer; Hiroyuki Koga; Xiaoyi Sun; Daniel H Teitelbaum
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

8.  Angiotensin Converting Enzyme Gene Polymorphism and its Association with Hypertension in South Indian Population.

Authors:  Ipsita Choudhury; R Jothimalar; Arun Kumar Patra
Journal:  Indian J Clin Biochem       Date:  2012-05-05

9.  Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Authors:  Takashi Naito; Li-Jun Ma; Haichun Yang; Yiqin Zuo; Yiwei Tang; Jee Young Han; Valentina Kon; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-30

10.  IL-8/CXCL8 Upregulates 12-Lipoxygenase Expression in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats.

Authors:  Jung Hae Kim; Young Jin Kang; Hee Sun Kim
Journal:  Immune Netw       Date:  2009-06-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.